Age-Related Macular Degeneration trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Age-Related Macular Degeneration. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month7 studies across 5 companies, in the next 180 days.
August 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| 4151.T | Kyowa Kirin Co., Ltd. | Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationNCT06116890Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline | Phase 2 | Active, not recruiting | 2026-08-31 | in 11 d | 2025-10-30 |
| ABBV | AbbVie | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)NCT04514653Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) score | Phase 2 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2026-02-27 |
| HROW | Harrow Inc | Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsNCT07456826Proportion of Participants Achieving Successful Ocular Surface Anesthesia | Phase 4 | Enrolling by invitation | Aug 2026 | ≤ 11 d | 2026-04-07 |
| KOD | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKNCT06556368Best corrected visual acuity (BCVA) | Phase 3 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2026-04-29 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDNCT05407636Mean change from baseline in Best Corrected Visual Acuity (BCVA) | Phase 3 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-08-03 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDNCT04704921Mean change from baseline in Best Corrected Visual Acuity (BCVA) | Phase 2/3 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-04-28 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| OCUL | Ocular Therapeutix, Inc. | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNCT06495918Best Corrected Visual Acuity (BCVA) | Phase 3 | Active, not recruiting | 2027-01-08 | in 141 d | 2025-06-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Age-Related Macular Degeneration
most recently updated first79 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyNCT06541704Growth rate (slope) of total GA lesion area (mm^2 /year) from baseline, measured by Fundus Autofluorescence (FAF) | Phase 3 | Recruiting | Drug: Pozelimab, Cemdisiran, Placebo | Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) | 975 | 2024-10-30 | 2028-07-31 | in 711 d | 2026-08-17 |
| AMGN | Amgen | $229.9B | A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationNCT07614776Change From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score | Phase 3 | Recruiting | Drug: ABP 938 8 mg, Aflibercept (US) 8 mg | Neovascular Age-related Macular Degeneration, nAMD | 304 | 2026-05-27 | 2027-07-31 | in 345 d | 2026-08-17 |
| ABBV | AbbVie | $457.5B | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)NCT07007065Annualized intravitreal anti-VEGF injection rate | Phase 3 | Recruiting | Drug: Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control | Neovascular Age-related Macular Degeneration | 561 | 2025-11-05 | Mar 2033 | ≤ 2,415 d | 2026-08-14 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular DegenerationNCT06970665Number of participants with Treatment Emergent Adverse Events (TEAEs) | Phase 4 | Active, not recruiting | Drug: avacincaptad pegol | Geographic Atrophy, Age-Related Macular Degeneration | 17 | 2025-07-08 | 2027-06-30 | in 314 d | 2026-08-12 |
| ABBV | AbbVie | $457.5B | Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDNCT05210803Incidences of ocular Adverse Events and any Serious Adverse Events | Phase 2 | Enrolling by invitation | Drug: Standard of Care, Ranibizumab | Neovascular Age-Related Macular Degeneration (nAMD) | 116 | 2021-12-20 | Jul 2031 | ≤ 1,806 d | 2026-08-05 |
| OTLK | Outlook Therapeutics, Inc. | $170M | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT03834753results2026-08-03Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA) | Phase 3 | Completed | Biological: bevacizumab, ranibizumab | Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | 228 | 2019-06-25 | 2021-06-07actual | — | 2026-08-03 |
| ABBV | AbbVie | $457.5B | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDNCT05407636Mean change from baseline in Best Corrected Visual Acuity (BCVA) | Phase 3 | Active, not recruiting | Genetic: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2 · Biological: Aflibercept (EYLEA®) | AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV | 735 | 2022-01-13 | Oct 2026 | ≤ 72 d | 2026-08-03 |
| OTLK | Outlook Therapeutics, Inc. | $170M | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT06190093results2026-06-30Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8 | Phase 3 | Completed | Biological: bevacizumab, ranibizumab | Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration | 400 | 2024-01-24 | 2024-11-07actual | — | 2026-07-23 |
| OTLK | Outlook Therapeutics, Inc. | $170M | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal DisordersNCT04516278results2026-07-17Number of Participants With Adverse Events | Phase 3 | Completed | Biological: bevacizumab | Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema | 197 | 2020-10-01 | 2021-02-10actual | — | 2026-07-17 |
| SNY | Sanofi | — | A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular DegenerationNCT06660667Incidence and severity of ocular treatment emergent adverse event (TEAEs) | Phase 1/2 | Active, not recruiting | Biological: SAR402663 · Drug: Diluent | Neovascular Age-related Macular Degeneration | 66 | 2024-11-21 | 2027-05-18 | in 271 d | 2026-07-16 |
| ABBV | AbbVie | $457.5B | Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationNCT07160179Number of Participants Experiencing Adverse Events | Phase 1/2 | Recruiting | Drug: ABBV-6628, SYFOVRE | Geographic Atrophy, Age-Related Macular Degeneration | 66 | 2025-08-13 | Oct 2029 | ≤ 1,168 d | 2026-07-13 |
| OCUL | Ocular Therapeutix, Inc. | $2.4B | Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 StudyNCT07516132Incidence and severity of treatment-emergent adverse events (TEAEs) from Baseline (Day 1) through Week 144 | Phase 3 | Recruiting | Drug: OTX-TKI | Neovascular Age-Related Macular Degeneration (nAMD) | 850 | 2026-04-27 | 2030-08-01 | in 1,442 d | 2026-07-01 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)NCT05989126results2026-05-28Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS | Phase 3 | Completed | Drug: aflibercept 8 mg PFS | Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) | 35 | 2024-04-15 | 2024-05-31actual | — | 2026-05-28 |
| KOD | Kodiak Sciences Inc | $2.6B | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKNCT06556368Best corrected visual acuity (BCVA) | Phase 3 | Active, not recruiting | Drug: Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept | Wet Age-related Macular Degeneration | 675 | 2024-08-23 | Aug 2026 | ≤ 11 d | 2026-04-29 |
| ABBV | AbbVie | $457.5B | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDNCT04704921Mean change from baseline in Best Corrected Visual Acuity (BCVA) | Phase 2/3 | Active, not recruiting | Genetic: ABBV-RGX-314, ABBV-RGX-314 · Biological: Ranibizumab (LUCENTIS®) | AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization | 671 | 2020-12-29 | Dec 2026 | ≤ 133 d | 2026-04-28 |
| OTLK | Outlook Therapeutics, Inc. | $170M | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal DisordersNCT05112861Frequency and incidence of treatment-emergent adverse events following intravitreal injections of ONS-5010 in vials or PFS | Phase 3 | Active, not recruiting | Biological: bevacizumab | Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema | 120 | 2021-11-15 | Dec 2027 | ≤ 498 d | 2026-04-22 |
| FDMT | 4D Molecular Therapeutics | $733M | Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNCT07064759Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52 | Phase 3 | Recruiting | Biological: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Neovascular Age-Related Macular Degeneration (nAMD) | 480 | 2025-07-22 | Nov 2028 | ≤ 833 d | 2026-04-16 |
| HROW | Harrow Inc | $1.5B | Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsNCT07456826Proportion of Participants Achieving Successful Ocular Surface Anesthesia | Phase 4 | Enrolling by invitation | Drug: Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2% · Procedure: Sham Subconjunctival Injection | Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR) | 236 | 2026-03-31 | Aug 2026 | ≤ 11 d | 2026-04-07 |
| ABBV | AbbVie | $457.5B | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)NCT04514653Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) score | Phase 2 | Active, not recruiting | Biological: Ranibizumab · Genetic: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, ABBV-RGX-314 Dose 4 · Drug: Local Steroid, Topical Steroid | Neovascular Age-Related Macular Degeneration (nAMD) | 146 | 2020-08-25 | Aug 2026 | ≤ 11 d | 2026-02-27 |
| FDMT | 4D Molecular Therapeutics | $733M | 4D-150 in Patients With Neovascular (Wet) Age-Related Macular DegenerationNCT05197270Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant changes in safety parameters | Phase 1/2 | Recruiting | Biological: 4D-150 IVT, Aflibercept IVT | Neovascular (Wet) Age-Related Macular Degeneration | 215 | 2021-12-09 | Mar 2027 | ≤ 223 d | 2026-02-12 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationNCT06116890Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline | Phase 2 | Active, not recruiting | Drug: KHK4951, Aflibercept Injection | Neovascular Age-Related Macular Degeneration (nAMD) | 180 | 2024-01-31 | 2026-08-31 | in 11 d | 2025-10-30 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)NCT06491914Occurrence of treatment-emergent adverse events (TEAEs) | Phase 3 | Active, not recruiting | Drug: Aflibercept 8 mg | Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | 1,118 | 2024-07-24 | 2025-08-26actual | — | 2025-10-15 |
| OCUL | Ocular Therapeutix, Inc. | $2.4B | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNCT06495918Best Corrected Visual Acuity (BCVA) | Phase 3 | Active, not recruiting | Drug: OTX-TKI, Aflibercept, Aflibercept | Neovascular Age-related Macular Degeneration | 825 | 2024-11-27 | 2027-01-08 | in 141 d | 2025-06-17 |
| OCUL | Ocular Therapeutix, Inc. | $2.4B | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular DegenerationNCT06223958Best corrected visual acuity (BCVA) | Phase 3 | Active, not recruiting | Drug: OTX-TKI (axitinib implant), Aflibercept | Neovascular Age-Related Macular Degeneration | 344 | 2024-01-29 | 2026-04-29 | — | 2025-04-18 |
| CGTX | Cognition Therapeutics | $93M | Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).NCT05893537Change from baseline in Geographic Atrophy (GA) lesion area over 104 weeks in the study eye. | Phase 2 | Terminatedsponsor's stated reason: The trial was closed as part of a strategic business decision. | Drug: Active Comparator CT1812, Placebo Comparator | Age-Related Macular Degeneration | 100 | 2023-06-16 | 2025-03-04actual | — | 2025-04-16 |
| OTLK | Outlook Therapeutics, Inc. | $170M | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT03844074Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) score | Phase 3 | Completed | Biological: bevacizumab, ranibizumab | Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | 61 | 2018-10-01 | 2020-07-23actual | — | 2025-03-19 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)NCT03815825Rate of Change from Baseline in the Geographic Atrophy (GA) Area at Week 49, as Assessed by Retinal Imaging | Phase 2 | Completed | Drug: IONIS-FB-LRx, Placebo | Macular Degeneration, Geographic Atrophy | 332 | 2019-03-04 | 2024-04-18actual | — | 2025-03-07 |
| REGN | Regeneron Pharmaceuticals | $76.1B | An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World SettingNCT06398080observationalMean prior treatment interval during the one-year period before study enrollment compared to the last assigned treatment interval during the study | — | Withdrawnsponsor's stated reason: Sponsor Decision | Drug: aflibercept 8 mg | Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment | 0 | 2024-12-12 | 2028-01-03 | in 501 d | 2024-11-25 |
| ABBV | AbbVie | $457.5B | RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)NCT04832724RGX-314 target protein concentration in aqueous humor | Phase 2 | Completed | Genetic: RGX-314 | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 60 | 2021-02-22 | 2023-10-02actual | — | 2024-09-05 |
| KOD | Kodiak Sciences Inc | $2.6B | A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.NCT04049266results2024-07-18Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48 and 52, Full Analysis Set Year 1 | Phase 2/3 | Terminatedsponsor's stated reason: Primary Endpoint Not Met | Drug: KSI-301, Aflibercept · Other: Sham Procedure | Wet Macular Degeneration | 559 | 2019-10-08 | 2021-11-17actual | — | 2024-07-18 |
| OCUL | Ocular Therapeutix, Inc. | $2.4B | CLN-0046: Treatment of AMD Subjects With OTX-TKINCT03630315Incidence of treatment emergent adverse events for each subject | Phase 1 | Completed | Drug: OTX-TKI, OTX-TKI, OTX-TKI, OTX-TKI, Anti-VEGF, OTX-TKI, Anti-VEGF | Neovascular Age-related Macular Degeneration | 29 | 2019-02-18 | 2024-01-10actual | — | 2024-07-10 |
| KOD | Kodiak Sciences Inc | $2.6B | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)NCT04964089results2024-05-02Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. | Phase 3 | Completed | Drug: KSI-301, Aflibercept · Other: Sham Procedure | Wet Age-related Macular Degeneration | 557 | 2021-06-23 | 2023-03-28actual | — | 2024-07-03 |
| ABBV | AbbVie | $457.5B | Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyNCT03999801Incidence of ocular adverse events and any serious adverse events in the study eye | Phase 2 | Enrolling by invitation | Genetic: RGX-314 | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | 865 | 2019-05-31 | Dec 2028 | ≤ 864 d | 2024-06-17 |
| KOD | Kodiak Sciences Inc | $2.6B | Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVONCT03790852Incidence of ocular (study eye) and systemic adverse events | Phase 1 | Terminatedsponsor's stated reason: All patients past planned primary endpoint; decision by Sponsor to wind down open-label follow-up activities. | Drug: KSI-301 | Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema | 121 | 2018-12-26 | 2021-06-02actual | — | 2024-03-20 |
| OCUL | Ocular Therapeutix, Inc. | $2.4B | Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular DegenerationNCT04989699Safety and Tolerability | Phase 1 | Completed | Drug: OTX-TKI/Sham, Aflibercept/Sham | Neovascular Age-Related Macular Degeneration | 21 | 2021-07-28 | 2023-02-06actual | — | 2024-01-26 |
| XBRANE.ST | Xbrane Biopharma AB | $1.3B | Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMDNCT03805100results2023-11-13Change in Best Corrected Visual Acuity (BCVA) | Phase 3 | Completed | Biological: Ranibizumab | Macular Degeneration | 582 | 2019-04-19 | 2021-05-11actual | — | 2023-11-13 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular DegenerationNCT04126317results2023-08-14Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) | Phase 2 | Completed | Drug: aflibercept, High-dose aflibercept | Neovascular (Wet) Age-Related Macular Degeneration | 106 | 2019-11-04 | 2021-05-14actual | — | 2023-08-14 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular DegenerationNCT04594681Number of participants with adverse events | Phase 1 | Terminatedsponsor's stated reason: The Sponsor judged that the objectives of this Phase 1 study were satisfied, and the study was terminated after the completion of Cohort 3 Step 3. | Drug: Placebo, KHK4951 | Healthy Volunteers, Wet Age-related Macular Degeneration | 116 | 2020-09-16 | 2022-08-26actual | — | 2023-05-18 |
| RGNX | REGENXBIO Inc. | $731M | Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD TrialNCT03066258results2023-05-16Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)) | Phase 1/2 | Completed | Genetic: RGX-314 | Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration | 42 | 2017-03-29 | 2019-11-24actual | — | 2023-05-16 |
| PFE | Pfizer | $155.3B | Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic AtrophyNCT01003691results2022-05-12Number of Participants With Toxicity or Intolerable Dose Criteria | Phase 1 | Completed | Biological: RN6G, Placebo | Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration | 24 | 2010-08-05 | 2013-03-05actual | — | 2022-05-12 |
| 196170.KQ | Alteogen, Inc. | $12.1B | Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMDNCT04058535Occurrences of adverse events | Phase 1 | Completed | Biological: Eylea, ALT-L9 | Neovascular Age-related Macular Degeneration | 28 | 2020-02-05 | 2020-12-22actual | — | 2022-01-20 |
| BLCO | Bausch & Lomb Incorporated | $6.1B | Extension Study to Gather Data on Effect of Macugen on the Corneal EndotheliumNCT01573572results2020-10-14Change From Baseline in Mean Endothelial Cell Density | Phase 4 | Completed | Drug: pegaptanib sodium injection | Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema | 131 | 2010-04-22 | 2019-11-14actual | — | 2021-01-08 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)NCT02418754results2020-10-26Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12 | Phase 2 | Terminatedsponsor's stated reason: No additional efficacy seen with REGN2176-3 over aflibercept alone | Drug: REGN2176-3, Intravitreal Aflibercept Injection (IAI) | Neovascular Age-Related Macular Degeneration | 505 | 2015-05-05 | 2016-08-17actual | — | 2020-10-26 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)NCT03446144Efficacy of IONIS-FB-Lrx | Phase 2 | Withdrawnsponsor's stated reason: Business objective change, no safety or efficacy concerns | Drug: IONIS-FB-Lrx, Placebo (sterline saline 0.9%) | Geographic Atrophy, Age Related Macular Degeneration | 0 | 2018-03-16 | 2018-10-10actual | — | 2019-08-13 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal InjectionNCT02713204results2019-05-07Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 | Phase 2 | Completed | Drug: REGN910-3, Intravitreal Aflibercept Injection (IAI) | Neovascular Age-Related Macular Degeneration | 365 | 2016-03-31 | 2017-10-03actual | — | 2019-05-07 |
| PFE | Pfizer | $155.3B | A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.NCT00549055results2010-10-27observationalChange From Baseline to Final Visit in Visual Acuity (VA) Score | — | Completed | Drug: Macugen | Neovascular Age-related Macular Degeneration | 38 | Nov 2007 | Oct 2009actual | — | 2018-12-06 |
| PFE | Pfizer | $155.3B | Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical PracticeNCT00787319results2013-08-13observationalChange From Baseline in Visual Acuity (VA) at Final Visit | — | Completed | Other: no intervention | Age-related Macular Degeneration | 108 | Jan 2010 | Jun 2012actual | — | 2018-12-06 |
| 4568.T | Daiichi Sankyo | $31.7B | Study of DS-7080a for the Treatment of Macular DegenerationNCT02530918Number of participants experiencing any treatment-emergent adverse event (TEAE) | Phase 1 | Completed | Drug: DS-7080a, Ranibizumab | Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | 56 | Jul 2015 | 2018-01-02actual | — | 2018-05-09 |
| NVS | Novartis | — | EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)NCT00470678Mean change in best-corrected visual acuity (BCVA) from Baseline, Month 4 and Month 12 as assessed with ETDRS (Early Treatment for Diabetic Retinopathy Study)-like charts at a distance of four meters | Phase 3 | Completed | Drug: ranibizumab | Choroidal Neovascularization, Age-Related Macular Degeneration | 95 | Jun 2007 | Nov 2008actual | — | 2016-11-18 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)NCT01997164Incidence of treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Drug: REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI) | Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | 20 | Nov 2014 | Oct 2015actual | — | 2016-01-12 |
| PFE | Pfizer | $155.3B | Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular DegenerationNCT00845273observationalFactors considered to affect the safety and/or efficacy of this drug. | — | Completed | Drug: Pegaptanib sodium | Macular Degeneration | 3,538 | Nov 2008 | Feb 2014actual | — | 2015-10-02 |
| PFE | Pfizer | $155.3B | Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular DegenerationNCT00877032results2015-03-31Incidence and Severity of Ocular Adverse Events (AEs) | Phase 1 | Completed | Biological: RN6G, Placebo | Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration | 57 | Apr 2009 | Jul 2011actual | — | 2015-03-31 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)NCT00964795results2015-03-23Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD | Phase 3 | Completed | Drug: Intravitreal Aflibercept Injection 2mg | Neovascular Age-related Macular Degeneration | 323 | Dec 2009 | Aug 2013actual | — | 2015-03-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMDNCT00320775Safety and tolerability, bioeffect | Phase 1 | Completed | Drug: VEGF Trap | Macular Degeneration | 51 | Jun 2005 | Jun 2008actual | — | 2015-03-18 |
| OPK | OPKO Health, Inc. | $1.0B | Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)NCT00557791Primary efficacy measure: The proportion of patients at week 60 in each group with a successful visual acuity outcome (as defined as avoidance of a 3, or more, line loss in vision). | Phase 3 | Withdrawnsponsor's stated reason: Study never initiated | Drug: Bevasiranib, ranibizumab | Age Related Macular Degeneration | 0 | Nov 2009 | Jul 2011 | — | 2015-03-06 |
| PFE | Pfizer | $155.3B | Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.NCT00820742observationalIncidence of adverse events and serious adverse events | — | Withdrawn | Drug: Macugen | Neovascular Age-related Macular Degeneration | 0 | Feb 2008 | May 2009 | — | 2015-03-05 |
| OPK | OPKO Health, Inc. | $1.0B | Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMDNCT00499590results2014-10-06Visual Acuity | Phase 3 | Terminated | Drug: bevasiranib, ranibizumab | Macular Degeneration | 338 | Aug 2007 | Mar 2009actual | — | 2014-10-06 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMDNCT00527423results2013-06-12Number of Participants With Adverse Events (AE) | Phase 2 | Completed | Drug: VEGF Trap Eye | Macular Degeneration | 157 | Aug 2007 | Oct 2011actual | — | 2013-06-12 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)NCT00509795results2012-04-16Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) | Phase 3 | Completed | Biological: ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Macular Degeneration | 1,217 | Aug 2007 | Sep 2010actual | — | 2012-12-28 |
| PFE | Pfizer | $155.3B | Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular DegenerationNCT00460408results2012-12-11observationalIncidence of Pertinent Ocular Adverse Events (POAEs) Per Injection | — | Completed | Drug: Macugen | Macular Degeneration | 501 | Aug 2006 | Feb 2012actual | — | 2012-12-11 |
| PFE | Pfizer | $155.3B | Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.NCT00858208results2012-04-11observationalChange From Baseline Visual Acuity (VA) at the Final Visit | — | Completed | Drug: pegaptanib sodium | Neovascular Age-related Macular Degeneration | 86 | Mar 2008 | Apr 2011actual | — | 2012-04-11 |
| PFE | Pfizer | $155.3B | An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMDNCT00327470results2010-12-17Mean Change From Baseline Through Week 54 in Distance Visual Acuity (VA) in Subjects With Early and Established CNV Lesions | Phase 4 | Terminatedsponsor's stated reason: See termination reason in detailed description. | Drug: Pegaptanib Sodium 0.3 mg | Age Related Macular Degeneration (AMD), Macular Degeneration, Choroidal Neovascularization (CNV) | 288 | Jul 2006 | Aug 2009actual | — | 2012-04-04 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)NCT00320788results2012-03-01Mean Change of CR/LT From Baseline at Week 12 | Phase 2 | Completed | Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Macular Degeneration | 159 | Apr 2006 | Jun 2008actual | — | 2012-03-01 |
| PFE | Pfizer | $155.3B | Macugen Observational StudyNCT00735943results2011-08-16observationalPercentage of Participants Showing Stabilization, Improvement or Deterioration of Visual Acuity (VA) | — | Terminatedsponsor's stated reason: See termination reason in detailed description. | Other: No intervention | Vascular Endothelial Growth Factor, Macular Degeneration | 22 | Nov 2008 | Aug 2010actual | — | 2011-08-29 |
| PFE | Pfizer | $155.3B | A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular DegenerationNCT00090532To evaluate the ocular and systemic safety of the study drug | Phase 1/2 | Terminatedsponsor's stated reason: This study was terminated due to a lack of efficacy. | Drug: AG-013,958 | Age-Related Macular Degeneration | 155 | Jan 2004 | — | — | 2011-05-27 |
| PFE | Pfizer | $155.3B | Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular DegenerationNCT00239928results2011-05-04Summary of Adverse Events | Phase 2 | Completed | Drug: pegaptanib sodium | Macular Degeneration | 61 | Sep 2005 | Nov 2008actual | — | 2011-05-12 |
| NVS | Novartis | — | Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)NCT00433017results2011-02-04Change From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12. | Phase 2/3 | Terminatedsponsor's stated reason: Study was terminated based on the results of analyses performed as planned at Month 12. | Drug: Verteporfin Photodynamic Therapy, Ranibizumab, Placebo | Macular Degeneration, Choroidal Neovascularization | 255 | May 2007 | Jul 2009actual | — | 2011-04-21 |
| NVS | Novartis | — | Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal NeovascularizationNCT00436553results2011-04-19Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 | Phase 3 | Completed | Drug: Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo | Macular Degeneration, Choroidal Neovascularization | 321 | Feb 2007 | Oct 2009actual | — | 2011-04-19 |
| NVS | Novartis | — | Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)NCT00275821results2011-03-16Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12 | Phase 3 | Completed | Drug: Ranibizumab 0.3 mg - 3 times monthly, then quarterly, Ranibizumab 0.5 mg - 3 times monthly, then quarterly, Ranibizumab 0.3 mg monthly | Age Related Macular Degeneration | 353 | Dec 2005 | Jan 2008actual | — | 2011-03-16 |
| NVS | Novartis | — | SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular DegenerationNCT00331864results2011-01-04Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye | Phase 3 | Completed | Drug: Ranibizumab | Age Related Macular Degeneration, Choroidal Neovascularization | 531 | Apr 2006 | Apr 2008actual | — | 2011-02-18 |
| PFE | Pfizer | $155.3B | Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular DegenerationNCT01245387results2011-01-07observationalVisual Acuity (VA) | — | Completed | Drug: Pegaptanib | Macular Degeneration, Age-related Macular Degeneration, Neovascular Macular Degeneration | 1,001 | Aug 2006 | Dec 2009actual | — | 2011-01-13 |
| PFE | Pfizer | $155.3B | A Study Of Early Markers Of Choroidal NeovascularizationNCT00902785observationalIdentify the sequence of change in the chorioretinal interface during the development of CNV and the progression from dry to neovascular AMD. | — | Terminated | Other: no drug | Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD), Early Markers | 100 | Mar 2008 | May 2010actual | — | 2010-11-10 |
| PFE | Pfizer | $155.3B | Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration LesionsNCT00324116results2009-10-02Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) | Phase 4 | Completed | Drug: pegaptanib sodium (Macugen) | Macular Degeneration | 81 | Jul 2006 | Aug 2008actual | — | 2010-03-23 |
| NVS | Novartis | — | Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)NCT00138632Safety as assessed by visual acuity measurements, ophthalmic examinations, vital signs, laboratory assessments, and adverse events up to 12 months | Phase 1/2 | Completed | Drug: PTK787, PTK787, Placebo | Wet Age-Related Macular Degeneration | 50 | Sep 2005 | Nov 2007actual | — | 2008-11-14 |
| OPK | OPKO Health, Inc. | $1.0B | Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular DegenerationNCT00259753change from baseline at the 12-week evaluation in macular edema as measured by optical coherence tomography. | Phase 2 | Completed | Drug: Bevasiranib | Macular Degeneration | 120 | Jul 2005 | Dec 2007actual | — | 2008-08-05 |
| OPK | OPKO Health, Inc. | $1.0B | Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5NCT00722384Complications, including those related to the intravitreal injection, and adverse events, and loss of lines of best-corrected visual acuity, slit lamp findings, lens opacification, intraocular pressure, fundus findings, and laboratory findings. | Phase 1 | Completed | Drug: bevasiranib, bevasiranib | Macular Degeneration | 15 | Aug 2004 | Aug 2007actual | — | 2008-07-25 |
| NVS | Novartis | — | Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular DegenerationNCT00503022Rates of adverse events and serious adverse events, as well as changes in ophthalmic evaluations, laboratory values, electrocardiograms (ECGs) and vital signs over 6 months, following single intravenous infusion of ACZ885. | Phase 1 | Completed | Drug: ACZ885 | Wet Age-Related Macular Degeneration | 20 | Jul 2006 | — | — | 2007-12-28 |
| PFE | Pfizer | $155.3B | Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)NCT00150202Visual aquity change from the baseline to 54 weeks after the first treatment is expected to be similar to that seen in the Western studies. | Phase 3 | Completed | Drug: pegaptanib sodium | Macular Degeneration | 90 | Jul 2004 | — | — | 2007-05-07 |
| NVS | Novartis | — | Photodynamic Therapy in Occult-Only Lesions (POOL)NCT00135837visual acuity measurements, baseline, 12 months | Phase 4 | Completed | Drug: Verteporfin for injection | Age-Related Macular Degeneration | 202 | Jun 2003 | — | — | 2006-06-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Age-Related Macular Degeneration is matched — 11 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration
- Wet Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Age Related Macular Degeneration
- nAMD
- AMD
- Age-related Macular Degeneration (AMD)
- Neovascular (Wet) Age-Related Macular Degeneration
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Age-Related Macular Degeneration” (a text search, wider than this page)